These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34063871)

  • 1. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.
    Fredsgaard L; Goksøyr L; Thrane S; Aves KL; Theander TG; Sander AF
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34063871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Purification of Tag/Catcher AP205-Based Capsid Virus-Like Particle Vaccines.
    Aves KL; Sander AF
    Methods Mol Biol; 2024; 2720():127-141. PubMed ID: 37775662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved
    Martinez FG; Zielke RA; Fougeroux CE; Li L; Sander AF; Sikora AE
    Infect Immun; 2023 Dec; 91(12):e0024523. PubMed ID: 37916806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice.
    Kang H; Martinez MR; Aves KL; Okholm AK; Wan H; Chabot S; Malik T; Sander AF; Daniels R
    iScience; 2024 Jun; 27(6):110038. PubMed ID: 38883830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
    Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
    Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
    Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
    Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines.
    Goksøyr L; Skrzypczak M; Sampson M; Nielsen MA; Salanti A; Theander TG; Remaley AT; De Jongh WA; Sander AF
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature.
    Aves KL; Janitzek CM; Fougeroux CE; Theander TG; Sander AF
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.
    Fausch SC; Da Silva DM; Kast WM
    Vaccine; 2005 Feb; 23(14):1720-9. PubMed ID: 15705478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
    Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
    J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
    Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
    Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines.
    Da Silva DM; Schiller JT; Kast WM
    Vaccine; 2003 Jul; 21(23):3219-27. PubMed ID: 12804851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines.
    Aves KL; Goksøyr L; Sander AF
    Viruses; 2020 Feb; 12(2):. PubMed ID: 32041299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers.
    Prentoe J; Janitzek CM; Velázquez-Moctezuma R; Soerensen A; Jørgensen T; Clemmensen S; Soroka V; Thrane S; Theander T; Nielsen MA; Salanti A; Bukh J; Sander AF
    NPJ Vaccines; 2022 Nov; 7(1):148. PubMed ID: 36379958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of a Soft Ensemble Vote Classifier for the Prediction of Chimeric Virus-Like Particle Solubility and Other Biophysical Properties.
    Vormittag P; Klamp T; Hubbuch J
    Front Bioeng Biotechnol; 2020; 8():881. PubMed ID: 32850736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types.
    Chen X; Liu H; Wang Z; Wang S; Zhang T; Hu M; Qiao L; Xu X
    Oncotarget; 2017 Sep; 8(38):63333-63344. PubMed ID: 28968993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Display of Streptococcus iniae α-Enolase on the Surface of Virus-Like Particles (VLPs) of Nervous Necrosis Virus (NNV) Using SpyTag/SpyCatcher.
    Yang JI; Kim KH
    Mar Biotechnol (NY); 2022 Dec; 24(6):1066-1072. PubMed ID: 36171522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging Immunofocusing and Virus-like Particle Display to Enhance Antibody Responses to the Malaria Blood-Stage Invasion Complex Antigen PfCyRPA.
    Björnsson KH; Bassi MR; Knudsen AS; Aves KL; Morella Roig È; Sander AF; Barfod L
    Vaccines (Basel); 2024 Jul; 12(8):. PubMed ID: 39203985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.